Vaxcyte (PCVX) Cash from Financing Activities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash from Financing Activities data on file, last reported at $601.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 79159.95% year-over-year to $601.6 million in Q1 2026; TTM through Mar 2026 was $602.8 million, a 63.04% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 99.92% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $601.6 million, up from $2.4 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for PCVX reached as high as $1.5 billion in Q3 2024 and fell as low as -$3.7 million in Q3 2025.
• Historically, Cash from Financing Activities has averaged $267.9 million across 5 years, with a median of $48.6 million in 2023.
• Across the five-year window, Cash from Financing Activities plunged 100.24% in 2025 and jumped 79159.95% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $656.6 million in 2022, then slumped by 99.58% to $2.7 million in 2023, then soared by 79.41% to $4.9 million in 2024, then sank by 50.93% to $2.4 million in 2025, then soared by 24882.68% to $601.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $601.6 million in Q1 2026, $2.4 million in Q4 2025, and -$3.7 million in Q3 2025.